Patents Assigned to Vectura Inc.
  • Patent number: 11865210
    Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: January 9, 2024
    Assignee: VECTURA INC.
    Inventor: Kambiz Yadidi
  • Patent number: 11819569
    Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 21, 2023
    Assignee: VECTURA INC.
    Inventor: Kambiz Yadidi
  • Publication number: 20230277450
    Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 µm to about 10 µm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 7, 2023
    Applicant: Vectura Inc.
    Inventor: Kambiz YADIDI
  • Patent number: 11596603
    Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: March 7, 2023
    Assignee: Vectura Inc.
    Inventor: Kambiz Yadidi